产品
编 号：F335412
分子式：C23H20Cl2F2N2O2S
分子量：497.38
分子式：C23H20Cl2F2N2O2S
分子量：497.38
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 358970-97-5
产品详情
生物活性：
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
体内研究：
AVE1625 (10 mg/kg orally once daily), combined with Olanzapine (HY-14541) attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility.AVE1625 (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 (HY-15084B) or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory.Animal Model:Rats.
Dosage:30 mg/kg.
Administration:Oral gavage, single dose.
Result:Had free access to food during the preceding night (postprandial state) caused a pronounced reduction of food intake during the subsequent 10-12 h without differences intheir locomotor activity relative to that of the control group.Caused an increase in FFA and glycerol, indicating increased lipolysis from fat tissue.Immediately resulted in a pronounced increase in VCO2 and VO2, indicating increased oxidation of energetic substrates and increased TEE.
Animal Model:Female Hanover Wistar rats weighing 225 ± 8.6 g.
Dosage:10 mg/kg.
Administration:Orally once daily.
Result:Reduced their weight markedly within the first 3 days of treatment where upon animals maintained lower body weight, although they lost about 7.3 ± 1.3 g fat during the 12 days of treatment.
Drinabant (AVE1625) is an orally active CB1 receptor antagonist. Drinabant (AVE1625) inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
体内研究：
AVE1625 (10 mg/kg orally once daily), combined with Olanzapine (HY-14541) attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility.AVE1625 (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 (HY-15084B) or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory.Animal Model:Rats.
Dosage:30 mg/kg.
Administration:Oral gavage, single dose.
Result:Had free access to food during the preceding night (postprandial state) caused a pronounced reduction of food intake during the subsequent 10-12 h without differences intheir locomotor activity relative to that of the control group.Caused an increase in FFA and glycerol, indicating increased lipolysis from fat tissue.Immediately resulted in a pronounced increase in VCO2 and VO2, indicating increased oxidation of energetic substrates and increased TEE.
Animal Model:Female Hanover Wistar rats weighing 225 ± 8.6 g.
Dosage:10 mg/kg.
Administration:Orally once daily.
Result:Reduced their weight markedly within the first 3 days of treatment where upon animals maintained lower body weight, although they lost about 7.3 ± 1.3 g fat during the 12 days of treatment.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备